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Background
To date there is no validated peripheral biomarker to
assist with the clinical diagnosis of Alzheimer’s disease
(AD). On the other hand, platelet proteins have been
studied as AD biomarkers with relative success. In the
present study we investigated whether platelet BACE1
levels differ between AD and cognitively normal (CN)
control patients.
Materials and methods
We collected blood samples from 12 CN and 15 AD sub-
jects using a standardized procedure. All samples were
processed within 5-60 min after collection. Blood fractions
were separated by successive centrifugations: red blood
cells, platelet-rich fraction, and platelet-poor plasma. Both
platelet and plasma samples were analyzed using a newly
developed BACE1 ELISA method and Western blotting.
Results
ELISA analysis showed that platelet BACE1 levels were
significantly lower in AD compare to CN subjects (12%
decrease, p<0.05). These data were supported by Western
blotting which indicated that several BACE1 isoforms
(37, 45, 56, 70 kDa) were significantly less abundant in
AD platelets. However, no significant difference between
the two groups was noted in plasma fractions.
Conclusions
Our pilot study suggests that circulating platelets possess
less BACE1 protein AD subjects. This provides evidence
for testing platelet BACE1 levels as a peripheral AD bio-
marker using our novel, sensitive and inexpensive ELISA
method. We are currently investigating this hypothesis
using larger groups as well as Parkinson’s disease subjects
to verify the specificity of the approach.
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